- Home
- EOLS vs CSTL Comparison
EOLS vs CSTL Comparison
Compare EOLS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOLS
- CSTL
- Stock Information
- Founded
- EOLS 2012
- CSTL 2007
- Country
- EOLS United States
- CSTL United States
- Employees
- EOLS N/A
- CSTL N/A
- Industry
- EOLS Biotechnology: Pharmaceutical Preparations
- CSTL Medical Specialities
- Sector
- EOLS Health Care
- CSTL Health Care
- Exchange
- EOLS Nasdaq
- CSTL Nasdaq
- Market Cap
- EOLS 589.3M
- CSTL 561.9M
- IPO Year
- EOLS 2018
- CSTL 2019
- Fundamental
- Price
- EOLS $9.53
- CSTL $16.07
- Analyst Decision
- EOLS Strong Buy
- CSTL Strong Buy
- Analyst Count
- EOLS 5
- CSTL 6
- Target Price
- EOLS $23.75
- CSTL $37.67
- AVG Volume (30 Days)
- EOLS 889.3K
- CSTL 423.5K
- Earning Date
- EOLS 08-05-2025
- CSTL 08-04-2025
- Dividend Yield
- EOLS N/A
- CSTL N/A
- EPS Growth
- EOLS N/A
- CSTL N/A
- EPS
- EOLS N/A
- CSTL N/A
- Revenue
- EOLS $275,463,000.00
- CSTL $347,083,000.00
- Revenue This Year
- EOLS $33.42
- CSTL N/A
- Revenue Next Year
- EOLS $33.18
- CSTL $1.36
- P/E Ratio
- EOLS N/A
- CSTL N/A
- Revenue Growth
- EOLS 25.38
- CSTL 38.43
- 52 Week Low
- EOLS $8.67
- CSTL $15.45
- 52 Week High
- EOLS $17.82
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- EOLS 51.00
- CSTL 31.25
- Support Level
- EOLS $9.12
- CSTL $16.16
- Resistance Level
- EOLS $10.20
- CSTL $17.31
- Average True Range (ATR)
- EOLS 0.40
- CSTL 0.79
- MACD
- EOLS 0.05
- CSTL -0.40
- Stochastic Oscillator
- EOLS 44.17
- CSTL 1.64
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.